Greenhouse Capital Partners United States

Greenhouse Capital Partner is a venture capital firm that was founded in 2006 and is based in Sausalito, California. The firm selectively makes equity investments into life science companies in seed stage and series A financing round, but it also provides growth equity to highly capital efficient companies that can achieve cash flow break-even within two years. The typical investment size ranges from $0.25 million to $2 million.The firm focuses on investments in US based companies.

Eric Desai
Principal 

H.I.G. BioVentures

H.I.G. BioVentures is the life science investment affiliate of H.I.G. Capital and has offices across the USA. H.I.G. BioVentures has assets under management of $4m and is investing from its second fund which closed at $268m in 212. The firm typically makes initial equity investments of $3-7m with the potential to invest up to $2m over the life of an investment. While most of H.I.G. BioVentures? portfolio companies are US-based the firm will consider opportunities worldwide.
Enoch Kariuki
Vice President 

HealthQuest Capital United States

Sofinnova Ventures was founded in 1974 and is based in Menlo Park, CA. The firm has approximately $1b of assets under management, and makes life science investments from two fund families; the main Sofinnova Ventures fund and Sofinnova HealthQuest Capital. Sofinnova Venture Partners IX closed at $500 million in 2014, and the debut HealthQuest fund closed at $110 million in 2014. The firm makes investments in the form of equity (preferred stock) and is an activist investor; the firm prefers to lead investments, take a board seat at its portfolio companies and be actively involved in company management. Sofinnova Ventures plans to make 4-6 new investments in life science companies in 2014. 

The Sofinnova Ventures main fund invests in biopharmaceuticals and typically makes initial investments of $5-15m, with the potential for a total investment of $15-30m. The fund invests in companies based in North America or Europe. 

HealthQuest Capital invests in non-biopharmaceutical life science and medtech companies and typically makes initial investments of $2-3m, with the potential for total investments of $5-6m. HealthQuest Capital is a venture growth fund focused on commercial-stage technologies, and only invests in companies headquartered in North America (particularly the US Southeast or West Coast).

Garheng Kong
Garheng Kong
Managing Partner 
Randy Scott
Randy Scott
LinkedIn logo Partner 

Hercules Technology Growth Capital Inc.

Hercules Technology Growth Capital is a Private Equity company founded in 23 Headquartered in Palo Alto California with additional offices in Boston Boulder New York and McLean. The firm manages an evergreen structure and primarily provides high-growth companies in the life science space with senior secured debt financing. The firm can allocate up to $5 million per investment. The firm is very flexible with deal structures that can be customized to help companies reach their key milestones. The firm primarily invests in companies headquartered in the US but has the ability to invest overseas as well.
Janice Borque
Managing Director Life Sciences 

Horizon Technology Finance United States

Horizon Technology Finance is a venture lending, investment and financial services management company that was founded in 2003 and is headquartered in Farmington, Ct with additional offices in Walnut Creek, CA and Reston, VA. The firm controls approximately $200 million in assets under management and look to provide senior or subordinate loans to companies in the range of $2 to $20 million dollars, and often syndicates much larger deals. The firm prefers to lead or co-lead investments that they are involved in and looks to be involved in 15 deals in the next 6-9 months. The firm provides capital to companies located throughout the United States and Canada.

Year Founded
2003
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Jerry Michaud

Hub Angels Investment Group

Hub Angels Investment Group is an angel group that was founded in 2 and is based in Cambridge Massachusetts. The firm manages a fund structure and recently closed its 4th fund making the total AUM of the group around $4 million. The firm makes investments ranging from $25 to $5 in equity for companies that are at least 12 months old. The firm makes investments ranging from four to eight years and prefers to invest in companies whose valuation does not exceed $1 million. Hub angels plans on making approximately 3 allocations over the next 6-9 months with stated interest in diagnostics and medical device companies.
Randy Barko
Member 

InterWest Partners

InterWest Partners founded in 1979 is a venture capital firm based in Menlo Park California. The firm?s primary focus is providing venture capital to early-stage healthcare and information technology companies. The firm has raised 1 funds to date with over $2.8 billion in committed capital. The firm?s tenth fund closed in 29 at $65 million. The firm generally invests in the Series A and B rounds, initially allocating $8-12 million and up to $2 million over the life of the investment. The firm primarily invests in US-based companies but will also selectively consider opportunities abroad. The firm is actively seeking new investment opportunities.
Doug Fisher
Partner 

Jump Capital United States

Jump Capital was founded in 2012 and is based in Chicago, with an additional office in San Francisco. The firm is investing from a $250m fund, and is interested in a variety of sectors including the life science field. For life science investments, Jump Capital typically allocates $2-15 million, and prefers to invest in Series B-C rounds. Jump Capital invests in the USA and Canada, and has previously invested in 6 healthcare companies.

Jump Capital invests in medical devices, diagnostics, digital and mobile health, and healthcare services. The firm is open to opportunities in any clinical indication. Jump Capital is only interested in devices and diagnostics that have in-human data.

Dr Garrett Vygantas
LinkedIn logo Partner 

JVC Investment Partners United States

JVC Investment Partners is a private investment firm that was founded in 2000 and is based in Chicago, Illinois. The firm focuses on investments in the healthcare industry. The investment size can vary greatly and is very flexible depending on each company’s needs. The firm provides venture capital and growth capital to healthcare companies. For early-stage investments, the firm targets companies that provide solutions for hospital acquired infections, medication errors, healthcare system operational efficiency enhancements and cost reductions, and chronic disease management, and it typically invests equity or convertible preferred equity in post series A rounds. For growth investments, the firm targets companies with compelling products and strong position in niche markets and with an EBITDA in excess of $2 million. The firm primarily invests in companies based in US.

David Jonas
Founder, President & CEO 
Jonathan Jonas
Partner 

Kineta United States

Kineta® is a nationally-recognized biotechnology company focused on developing leading edge therapeutics in three large high need therapeutic areas: autoimmune disease, viral disease and chronic pain. Our company is focused on the development of novel drug candidates each the outcome of years of scientific exploration and supported by an extensive body of peer-reviewed NIH-supported research.

Biotech Phase of Development
Technology Overview

Kineta® is developing a pipeline of next-generation medicines to respond to the needs of millions of people facing diseases around the world. Our scientific areas of expertise are immunology and neuropathic pain with research directed at curbing inflammation and returning the immune system to normal function. Kineta has five unique drug programs in development and each program represents a novel mechanism-of-action and has potential to result in a new class of drug. The innovative portfolio is derived from leading edge scientific research that taps into promising recently discovered cellular channels that control the body's defense mechanisms. Kineta’s drug programs are designed to enhance or modulate the natural human immune system and show great potential to be more effective, more tolerable and confer fewer side effects than existing drugs. We anticipate our products will be highly sought after by patients, healthcare providers and the pharmaceutical industry.

Alliance & Collaborations
27 Scientific and academic collaborations
Current Financing Needs

Series B round of $5M with follow on series C for an additional $20M.

Current Timeline

Autoimmune drug successfully completed phase I clinical trials and is currently in a phase 1B extension study to be completed 1st quarter.  In discussions with numerous large pharmaceutical and biotechnology companies around a licensing transaction.

Antiviral and pain programs are currently in pre-clinical development with high industry interest.  We are in significant partnering discussions around several of our anti-viral drug candidates.

Current Investors

We have raised $36M since 2008.  This has been augmented with an additional $52M in NIH funding.

Our current investors are accredited investors, high net worth individuals, Family Offices, a boutique PE group and the Iacocca Foundation.

IP Status
  Protected Pipeline Secured with a
Valuable IP Portfolio ØStrong IP across each development program ØProprietary expertise in innate immunity & autoimmunity Ø27 Patent Families (28 owned, 6 in-licensed) •45 Issued Patents •154 Pending country applications •7 Pre-nationalized PCT or provisional families
Management Team Highlights

Chuck Magness, PhD

CEO

Human Genome Project; Co-founded & Sold Illumigen Biosciences ($17M + 321M); Kineta Enterprise >$60M

Shawn Iadonato, PhD

CSO

Human Genome Project; Illumigen Biosciences; Grew 5 Kineta Programs; 1st Kv1.3 in Clinic; >$35M  R&D Funds

Craig Philips, MBA

Commercial Operations

 VP & GM, Schering Plough, VP & GM, Bayer, President & GM CTI

Blake Ilstrup, JD

General Counsel /

Corporate Dev.

Hundreds of transactions with Cooley and Venture Law Group, General Counsel of Qpass, 6 Kineta transactions

Rob Hedequist

Corporate Development

Major Accounts, Managed Care & Sales/ Marketing Pfizer and Amgen; National Director Schering–Plough

Dan Eramian

Corporate Communications

First VP of communications for Biotech Industry Organization; US DOJ Director of Public Affairs; SBA

Ken North

Corporate Development

Founding CEO Seattle Savings Bank; Past president Seattle Kiwanis, Chamber of Commerce; Seafair Commodores

Dan Burge, MD

Clinical

Trubion (CMO), VP Early Development Immunex, Amgen (early development on Enbrel)

Jeff Fellows

Regulatory

Global Regulatory Lead Amgen,  VP Regulatory Alder, VP Regulatory CTI,  First Kv1.3 in clinic, Sensipar Amgen

Mr Rob Hedequist
Senior Vice President Corporate Development 
Blake Ilstrup
Jacques Bouchy